Nona Biosciences
Shannon Spiliotis is an experienced events and marketing professional currently serving as Senior Manager of Events and Marketing at Nona Biosciences since December 2024. Prior to this role, Shannon owned and operated Spiliotis Events from January 2011 to December 2024, specializing in managing weddings and milestone events while creating tailored marketing programs. Shannon's background includes serving as Global Events Manager at Vizgen, focusing on the spatial genomics field, and holding event management roles at Charles River Laboratories, coordinating logistics for various industry tradeshows. Additionally, Shannon has experience in the publishing sector as Circulation Manager and Assistant Editor for NH Magazine's Bride. Educational qualifications include a Bachelor's degree in Business Administration from Merrimack College, an MBA in Marketing from Southern New Hampshire University, and a Master of Science in Project Management from Drexel University College of Engineering. Shannon also holds a certification in Wedding Planning from the Wedding Planning Institute.
This person is not in the org chart
This person is not in any teams
Nona Biosciences
Nona Biosciences is a global biotechnology company committed to providing a total solution for partners worldwide, from academies, biotech startups to biopharma giants. The integrated antibody discovery services range from antigen preparation, animal immunization, single B cell screening, to antibody lead generation and engineering, developability assessment and pharmacological evaluation, leveraging the advantages of Harbour Mice® platforms and the experienced therapeutic antibody discovery team. Harbour Mice® generates fully human monoclonal antibodies in two heavy and two light chains (H2L2) format, as well as heavy chain only (HCAb) format. Integrating Harbour Mice® and a single B cell cloning platform, Nona Biosciences is focused on driving global inventions of transformative next-generation drugs by diversified partnership strategies including co-discovery, platform and antibody discovery, and platform license. The values of the antibody discovery platforms and flexible partnership models have been well validated by more than 50 industry and academic partners within over 200 projects.